Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Lampertico

Showing results (1-10 of 348) with videos related to

Pageof 35
Sort By:
Journal of Hepatology|February 24, 2009
Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practicePietro Lampertico
Gut|August 22, 2014
Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?Pietro Lampertico
Journal of Hepatology|July 18, 2006
Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis BPietro Lampertico
Hepatology (Baltimore, Md.)|February 4, 2015
The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapyPietro Lampertico
Gut|October 29, 2013
Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to goPietro Lampertico
Gastroenterology & Hepatology|April 26, 2014
Discontinuation of nucleoside analogues in hepatitis B virus infectionPietro Lampertico
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association|March 17, 2012
Clinical implications of HBsAg quantification in patients with chronic hepatitis BMauro Viganò, Pietro Lampertico
Clinical Liver Disease|July 24, 2019
Mauro Viganò, Pietro Lampertico
Gastroenterology|September 24, 2013
Nucleos(t)ide analogs-based chemoprevention of liver cancer in hepatitis B patients: effective, yet in search of optimizationPietro Lampertico, Massimo Colombo
Hepatology (Baltimore, Md.)|February 19, 2024
HCC risk in patients who are HBeAg-positive and have chronic hepatitis B under long-term nucleos(t)ide analogue therapy: New insights from AsiaGeorge Papatherodoridis, Pietro Lampertico
Pageof 35

Showing results (1-10 of 348) with videos related to

Sort By:
Pageof 35
Journal of Hepatology|February 24, 2009
Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practicePietro Lampertico
Gut|August 22, 2014
Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?Pietro Lampertico
Journal of Hepatology|July 18, 2006
Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis BPietro Lampertico
Hepatology (Baltimore, Md.)|February 4, 2015
The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapyPietro Lampertico
Gut|October 29, 2013
Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to goPietro Lampertico
Gastroenterology & Hepatology|April 26, 2014
Discontinuation of nucleoside analogues in hepatitis B virus infectionPietro Lampertico
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association|March 17, 2012
Clinical implications of HBsAg quantification in patients with chronic hepatitis BMauro Viganò, Pietro Lampertico
Clinical Liver Disease|July 24, 2019
Mauro Viganò, Pietro Lampertico
Gastroenterology|September 24, 2013
Nucleos(t)ide analogs-based chemoprevention of liver cancer in hepatitis B patients: effective, yet in search of optimizationPietro Lampertico, Massimo Colombo
Hepatology (Baltimore, Md.)|February 19, 2024
HCC risk in patients who are HBeAg-positive and have chronic hepatitis B under long-term nucleos(t)ide analogue therapy: New insights from AsiaGeorge Papatherodoridis, Pietro Lampertico
Pageof 35